Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0011570 (depression)
 172,036 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Twenty-three patients with disseminated refractory malignancies each received a tailored combination of adriamycin-conjugated murine monoclonal antibodies. Tumors were typed using a panel of antibodies. Cocktails of up to six antibodies were selected based on binding greater than 80% of the malignant cells as tested by immunoperoxidase and flow cytometry. These monoclonal antibodies were then conjugated to Adriamycin and administered intravenously. Seventeen of 23 patients had reactions to the administration of immunoconjugates, but these were tolerable in all but two patients. Fever, chills, pruritus, and skin rash were by far the most common transitory reactions. All were well controlled with premedication. In several patients there was limited antigenic drift among various biopsies within the same patient over time. This observation confirms the necessity for the use of a cocktail of antibodies if one wishes to cover all tumor cells. Preliminary serologic evidence suggests that the development of an IgM antibody, which is specific against the mouse monoclonal antibody, has the specificity and sensitivity to predict clinical reactions. Selected patients were re-treated. One patient with chronic lymphocytic leukemia had re-treatment on three occasions and demonstrated regression of peripheral lymph nodes. Two patients with breast carcinoma had definite improvement in ulcerating skin lesions and two patients with tongue carcinoma had shrinkage of their lesions. In the course of the study free Adriamycin released from the monoclonal antibodies was discovered to be a limiting factor in the amount of antibody that could be administered. Up to 1 g of Adriamycin and up to 5 g of monoclonal antibody were administered. The limiting factor appeared to be a variable dissociation of active Adriamycin from the antibody that unpredictably caused hemopoietic depression. This study demonstrates the feasibility and reviews technical considerations in preparing immunoconjugate cocktails for patients with refractory malignancies. The major technical hurdle appears to be the selection of an effective conjugation method that can be used to optimally bind Adriamycin to monoclonal antibodies for targeted cancer therapy.
 ...
PMID:Adriamycin custom-tailored immunoconjugates in the treatment of human malignancies. 326 48

Psychiatric side-effects associated with acyclovir therapy are very rare in the medical literature. We present a case of depression with paranoid delusions in a patient with chronic lymphocytic leukemia that appeared after intravenous acyclovir treatment for herpes simplex infection. The clinical picture resolved following discontinuation of acyclovir and treatment with haloperidol and maprotiline. The patient's status was intact at an eight-month follow-up check. The few reports of psychiatric disorders due to acyclovir are reviewed and discussed.
 ...
PMID:Major depression with psychotic features associated with acyclovir therapy. 337 Nov 92

Rothia dentocariosa is part of the human oral flora and has only rarely been reported as a cause of clinical infection. We report the isolation of Rothia dentocariosa from the blood of a septicaemic patient with chronic lymphocytic leukaemia and bone marrow depression following treatment with clomipramine and zuclopentixol.
 ...
PMID:Rothia dentocariosa septicaemia in a patient with chronic lymphocytic leukaemia and toxic granulocytopenia. 343 59

Sixty-four persons with M-components in serum were detected in a health survey of 6995 subjects in 1964. After 20 years, data could be obtained on all 64. The 45 who had died included two cases of myeloma and one of malignant lymphoma. One of the myeloma cases had started as chronic lymphatic leukemia. Three of the 19 persons alive had an increase in the size of the M-component and depression of the background immunoglobulin, but they could not be diagnosed as myeloma cases. One had a rather large but not increasing M-component and an excess of light chains. She could be a third case of myeloma in this series.
 ...
PMID:A 20-year follow-up study of 64 subjects with M-components. 373 56

Eight previously treated and four untreated patients with B cell chronic lymphocytic leukemia (CLL) received 20 X 10(6) U/m2 recombinant leukocyte interferon clone A (rIFN-alpha A) intramuscularly three times a week for 8 weeks. None of the eight patients who had received prior chemotherapy exhibited objective evidence of tumor regression. Two of the four previously untreated patients responded with transient (90%) decreases in absolute lymphocyte counts lasting for 2 and 7 months. Toxicity was moderate, with all patients experiencing a flu-like syndrome requiring a 50% dose reduction. Half of the patients exhibited anorexia, weight loss, and a drop in performance status. The two responders had normal serum immunoglobulin levels prior to treatment, whereas 80% of non-responders had depressed levels. Treatment with rIFN-alpha A was associated with a depression of nonspecific and specific humoral immunity in assays employing cryopreserved autologous pretherapy CLL cells. No consistent effects were demonstrable in cytolytic assays with purified peripheral blood T cells as effector cells, including one that utilized autologous CLL target cells. rIFN-alpha A has limited antitumor activity in B cell CLL which is restricted to untreated patients with an early stage of disease. With the assays employed it was not possible to demonstrate that rIFN-alpha A could augment autologous antitumor immunity.
 ...
PMID:Recombinant leukocyte A interferon in B-cell chronic lymphocytic leukemia: in vivo effects on autologous antitumor immunity. 387 30

Haemolytic activities of the classical and alternative complement pathways, and levels of C1, C4, C3, factor B and C1 inhibitor (C1-INH) were measured in 85 serum samples from 46 patients with chronic lymphocytic leukaemia (CLL). Significantly decreased mean C1 and C4 levels were found, and the haemolytic activities of these components were low or low normal in more than 50% of the sera tested. In 15 sera from 5 patients a complement profile characteristic of acquired C1-IHN deficiency was observed. These results indicate that the depression of the activity of the classical complement pathway is a frequently occurring feature in CLL.
 ...
PMID:Depressed classical complement pathway activities in chronic lymphocytic leukaemia. 401 86

Low dose total body irradiation (TBI) administered in small fractional doses (5-10 cGy) for the treatment of disseminated malignancies such as chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma can be extremely toxic with substantial bone marrow depression. We elected to study bone marrow suppression following fractionated TBI in the rabbit. New Zealand white/female rabbits were thus treated with one of the following three schedules: (1) 3 fractions of 10 cGy per week; (2) 5 fractions of 10 cGy per week; and (3) 5 fractions of 25 cGy per week. Total doses ranged from 1050 to 2625 cGy and animals were sacrificed immediately, 4 weeks, or 8 weeks following completion of therapy. With the 10 cGy/day schedules, slight depression of total WBC counts and lymphocyte numbers occurred during and to the completion of irradiation followed by a rebound to greater than normal levels. With the 25 cGy schedule, a significant WBC and lymphocyte depression occurred at an accumulated dose of 1000 cGy and continued to decrease up to 2500 cGy, followed again by a rebound to greater than normal levels. The depression with the 25 cGy fractions was significantly greater than with the 10 cGy daily fractions. Thus, the severe and persistent peripheral blood count depression observed in CLL patients treated with TBI in small fractional doses was not reproduced in the normal rabbits. Possible explanations for this paradox are offered.
 ...
PMID:The paradoxes in patterns and mechanism of bone marrow regeneration after irradiation. 2. Total body irradiation. 639 45

The main complications from treatment of CLL with purine analogues are bone marrow depression resulting in cytopenia, immune suppression leading to infections, particularly opportunistic infections, and immune deregulation with autoimmune hemolytic anemia as the most common feature. These complications usually delay or even prevent further treatment, thus leading to a reduced clinical response. In order to achieve the greatest benefit from purine analogue therapy, it is important to be able to predict the risk of such complications, and to use a treatment strategy with optimal dose intensity, by prophylactic supportive care when required, and by early detection and adequate management of complications.
 ...
PMID:Complications in the treatment of CLL with purine analogues. 947 Oct 60

Overall, thirty-five patients with chronic lymphoid leukemia in the advanced stage were examined. Results of the findings obtained show that the first course of chemotherapy does not have significant effect on general lytic activity of complement and opsonic activity of blood serum but inhibits activity of classical and alternative paths of complement. Repeated courses of chemotherapy make for depression of general lytic activity of complement as well as classical and alternative paths of the complement system.
 ...
PMID:[The effect of cytostatic therapy on the indices of the humoral factors in body nonspecific reactivity in patients with chronic lympholeukemia]. 967 Jun 68

Micellar electrokinetic capillary chromatography (MECC) was applied to develop an analytical method for quantitation of ribonucleoside triphosphates (rNTPs) in human lymphoid cells obtained from patients with B-chronic lymphocytic leukaemia (B-CLL) and cutaneous lymphomas. The results of this analysis showed a significant depression of intracellular rNTPs in patients with B-CLL, compared with rNTPs of healthy controls. These data are in agreement with other studies in which rNTP separations were performed with traditional high-performance liquid chromatography. MECC has proved to be a useful tool for intracellular rNTPs determination, revealing possible new applications in the study of the metabolic state of human cells. In addition, this method can be useful in monitoring the effect of many drugs (antiviral, antineoplastic) which interfere with nucleotide metabolism.
 ...
PMID:Quantitative analysis of ribonucleoside triphosphates in human lymphoid cells by micellar electrokinetic capillary chromatography. 1050 15


<< Previous 1 2 3 4 Next >>